Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
International Journal of Molecular Sciences · 10.01.2023 · 24 (2) · 1361
DOI: 10.3390/ijms24021361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.01.2023. Verfasst von Camille Tlemsani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms, Osteosarcoma. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal CS. The diagnosis of CS combines radiological and histological data in conjunction with patient clinical presentations. Conventional CS is the most frequent subtype of CS (85%) and represents about 25% of primary bone tumors in adults; they can be categorized according to their bone location into central, peripheral, and periosteal chondrosarcomas. Central and peripheral CS differ at the molecular level with either IDH1/2 mutations or EXT1/2 mutations, respectively. CDKN2A/B deletions are also frequent in conventional CS, as well as COL2A1 mutations. Dedifferentiated CS develops when low-grade conventional CS transforms into a high-grade sarcoma and most frequently exhibits features of osteosarcoma, fibrosarcoma, or undifferentiated pleomorphic sarcoma. Their molecular characteristics are similar to conventional CS. Mesenchymal CS is a totally different pathological entity exhibiting recurrent translocations. Their clinical presentation and management are different too. The standard treatment of CSs is wide en-bloc resection. CS are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in an attempt to achieve local control in unresectable tumors. Chemotherapy is possibly effective in mesenchymal chondrosarcoma and is of uncertain value in dedifferentiated chondrosarcoma. Due to resistance to standard anticancer agents, the prognosis is poor in patients with metastatic or unresectable chondrosarcomas. Recently, the refined characterization of the molecular profile, as well as the development of new treatments, allow new therapeutic options for these rare tumors. The efficiency of IDH1 inhibitors in other malignancies suggests that these inhibitors will be part of IDH1/2 mutated conventional CS management soon. Other treatment approaches, such as PIK3-AKT-mTOR inhibitors, cell cycle inhibitors, and epigenetic or immune modulators based on improving our understanding of CS molecular biology, are emerging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
- INSERM U1016-CNRS UMR8104, Cochin Institute, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
- Department of Pathology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
- Department of Orthopedic Surgery, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
- Department of Genetics, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
ORCID-Profile: Camille Tlemsani, Sixtine De Percin, Eric Pasmant, Pascaline Boudou-Rouquette
Zitieren
APA
Tlemsani, C., Larousserie, F., De Percin, S., Audard, V., Hadjadj, D., Chen, J., Biau, D., Anract, P., Terris, B., Goldwasser, F., Pasmant, E., & Boudou-Rouquette, P. (2023). Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options. International Journal of Molecular Sciences, 24(2), 1361. https://doi.org/10.3390/ijms24021361
Vancouver
Tlemsani C, Larousserie F, De Percin S, Audard V, Hadjadj D, Chen J, et al. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options. International Journal of Molecular Sciences. 2023;24(2):1361. doi:10.3390/ijms24021361
BibTeX
@article{Tlemsani2023,
author = {Tlemsani, Camille and Larousserie, Frédérique and De Percin, Sixtine and Audard, Virginie and Hadjadj, Djihad and Chen, Jeanne and Biau, David and Anract, Philippe and Terris, Benoit and Goldwasser, François and Pasmant, Eric and Boudou-Rouquette, Pascaline},
title = {Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {2},
pages = {1361},
doi = {10.3390/ijms24021361}
}
EUVIMED